



## Preferred Drug List

# NEW DRUG REVIEW

**Proprietary Name:** Edurant™

**Common Name:** rilpivirine

**PDL Category:** Antiretrovirals- RTI-Non-Nucleoside Analogues

<u>Comparable Products</u>	<u>Preferred Drug List Status</u>
Sustiva®	Recommended

**Summary**

**Indications and Usage:** Indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in treatment naïve adult patients. <sup>1</sup>

**Mechanism of Action:** Inhibits HIV-1 replication by non-competitive inhibition of HIV-1 reverse transcriptase. <sup>1</sup>

**Dosage Forms:** Tablets: 25mg

**Recommended Dosage:** Recommended dose is 25mg once daily with a meal. <sup>1</sup>

**Common Adverse Drug Reactions:** Depression, insomnia, headache, rash. <sup>1</sup>

**Contraindications:** Co-administration with drugs where significant decreases in rilpivirine plasma concentrations may occur. <sup>1</sup>

**Manufacturer:** Tibotec Pharmaceuticals, Inc.

**Analysis:** Edurant™ is a non-nucleoside reverse transcriptase inhibitor (NNRTI) indicated in combination with other antiretroviral drugs for the treatment of HIV-1 infection in treatment naïve patients. In the studies used to gain FDA approval, Edurant™ was compared to Sustiva® in combination with other antiretroviral drugs in patients who had not received prior HIV therapy. Edurant™ was shown to be as effective as Sustiva® in reducing viral load. After 48 weeks of treatment, 83% of patients taking Edurant™ achieved viral suppression, compared to 80% with Sustiva®. In patients with a high viral load (> 100,000 copies per ml), 13% of patients experienced virologic failure with Edurant™, compared to 9% with Sustiva®. In addition, patients who failed therapy with Edurant™ developed more drug resistance compared to patients who failed Sustiva®. Alternatives are available, which have similar clinical efficacy and are more cost effective. Therefore, it is recommended that Edurant™ be added to the Recommended Drug List as a non-recommended drug.

**IME Recommendation:**

<input type="checkbox"/> Preferred Drug	<input type="checkbox"/> Recommended Drug
<input type="checkbox"/> Non-Preferred Drug	<input checked="" type="checkbox"/> Non-Recommended Drug
<input type="checkbox"/> Non-Preferred Drug with Conditions	

1. Edurant™ [package insert]. Raritan, NJ: Tibotec Pharmaceuticals, Inc.; 2011.